The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice
Open accessAbstract
Combined checkpoint blockade (e.g., PD1/PD-L1) with traditional clinical therapies can be hampered by side effects and low tumour-therapeutic outcome, hindering broad clinical translation. Here we report a combined tumour-therapeutic modality based on integrating nanosonosensitizers-augmented noninvasive sonodynamic therapy (SDT) with checkpoint-blockade immunotherapy. All components of the nanosonosensitizers (HMME/R837@Lip) are clinically approved, wherein liposomes act as carriers to co-encapsulate sonosensitizers (hematoporphyrin monomethyl ether (HMME)) and immune adjuvant (imiquimod (R837)). Using multiple tumour models, we demonstrate that combining nanosonosensitizers-augmented SDT with anti-PD-L1 induces an anti-tumour response, which not only arrests primary tumour progression, but also prevents lung metastasis. Furthermore, the combined treatment strategy offers a long-term immunological memory function, which can protect against tumour rechallenge after elimination of the initial tumours. Therefore, this work represents a proof-of-concept combinatorial tumour therapeutics based on noninvasive tumours-therapeutic modality with immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SDT can induce ICD and trigger anti-tumor immunity [88–91]”
From Nanosensitizer-assisted sonodynamic therapy for breast cancer (2025) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Cited by
Multifunctional sonosensitizers in sonodynamic cancer therapy
Son, S., Kim, J. H., Wang, X., Zhang, C., Yoon, S. A., Shin, J., Sharma, A., Lee, M. H., Cheng, L., Wu, J., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00648f · Cited by 1,150
Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy
Liang, S., Deng, X., Ma, P., Cheng, Z., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202003214 · Cited by 598
Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy
Deng, X., Shao, Z., & Zhao, Y. (2021) · Advanced Science · doi:10.1002/advs.202002504 · Cited by 590
Ultrafine Titanium Monoxide (TiO1+x) Nanorods for Enhanced Sonodynamic Therapy
Wang, X., Zhong, X., Bai, L., Xu, J., Gong, F., Dong, Z., Yang, Z., Zeng, Z., Liu, Z., & Cheng, L. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10228 · Cited by 532
Ultrasound‐Activated Sensitizers and Applications
Lin, X., Song, J., Chen, X., & Yang, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201906823 · Cited by 501
Metadata
- Authors
- Yue, W., Chen, L., Yu, L., Zhou, B., Yin, H., Ren, W., Liu, C., Guo, L., Zhang, Y., Sun, L., Zhang, K., Xu, H., & Chen, Y.
- Affiliations
- Tongji University (CN)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Zhang, Kun
- Chen, Yu
- ORCID
- Venue
- Nature Communications
- Published
- 2019-05-02
- Volume
- 10
- Issue
- 1
- Pages
- 2025-2025
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6497709
- OpenAlex
- W2942900492
- Cited by
- 590
- References
- 52
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 82 · 2023: 108 · 2022: 105 · 2021: 96 · 2020: 75 · 2019: 19
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (2016YFA0203700, 81725008, 81671695, 81501474, 81501473, 51672303, 51722211, 81601501, 81601502, 81771836,)
- Science and Technology Commission of Shanghai Municipality (18XD1404300, 14441900900, 16411971100)
- Program of Shanghai Subject Chief Scientist (18XD1404300)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- sonodynamic therapy, hematoporphyrin monomethyl ether, imiquimod, liposomes, PD-L1 blockade, immune checkpoint blockade, lung metastasis, cancer immunotherapy, immunological memory, combination cancer therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Imiquimod, Adjuvants, Immunologic, Animals, Combined Modality Therapy, Disease Models, Animal, Drug Screening Assays, Antitumor, Female, Hematoporphyrins, Humans, Immunotherapy, Liposomes, Mice, Inbred BALB C, Neoplasm Metastasis, Neoplasms, Ultrasonic Therapy, Treatment Outcome, Apoptosis, Cell Line, Tumor, Mice, Nanoparticles, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. https://app.cochat.ai/papers/10.1038/s41467-019-09760-3
- The paper
- Yue, W., Chen, L., Yu, L., Zhou, B., Yin, H., Ren, W., Liu, C., Guo, L., Zhang, Y., Sun, L., Zhang, K., Xu, H., & Chen, Y. (2019). Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nature Communications. https://doi.org/10.1038/s41467-019-09760-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.